关注
Stephen R. Saklad, Pharm.D., BCPP
Stephen R. Saklad, Pharm.D., BCPP
The University of Texas at Austin, Col of Pharmacy, Div of Pharmacotherapy & Translational Science
在 uthscsa.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Abuse and misuse of pregabalin and gabapentin
KE Evoy, MD Morrison, SR Saklad
Drugs 77, 403-426, 2017
4082017
Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance
MW Jann, SR Saklad, L Ereshefsky, AL Richards, CA Harrington, ...
Psychopharmacology 90, 468-470, 1986
1601986
Clinical pharmacokinetics of the depot antipsychotics
MW Jann, L Ereshefsky, SR Saklad
Clinical pharmacokinetics 10, 315-333, 1985
1481985
Effects of smoking on fluphenazine clearance in psychiatric inpatients.
L Ereshefsky, MW Jann, SR Saklad, CM Davis, AL Richards, NR Burch
Biological Psychiatry, 1985
1281985
Effects of carbamazepine on plasma haloperidol levels
MW Jann, L Ereshefsky, SR Saklad, DR Seidel, CM Davis, NR Burch, ...
Journal of clinical psychopharmacology 5 (2), 106-109, 1985
1271985
Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
L Ereshefsky, SR Saklad, MW Jann, CM Davis, A Richards, DR Seidel
The Journal of clinical psychiatry 45 (5 Pt 2), 50-59, 1984
1161984
Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview
CU Correll, E Kim, JK Sliwa, W Hamm, S Gopal, M Mathews, ...
CNS drugs 35 (1), 39-59, 2021
1122021
Guide to the management of clozapine-related tolerability and safety concerns
L Citrome, JP McEvoy, SR Saklad
Clinical schizophrenia & related psychoses 10 (3), 163-177, 2016
1102016
“Meta-guidelines” for the management of patients with schizophrenia
SM Stahl, DA Morrissette, L Citrome, SR Saklad, MA Cummings, ...
CNS spectrums 18 (3), 150-162, 2013
1042013
A review of NMDA receptors and the phencyclidine model of schizophrenia
SA Thornberg, SR Saklad
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 16 (1 …, 1996
1001996
Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients
L Ereshefsky, CM Davis, CA Harrington, MW Jann, JL Browning, ...
Journal of clinical psychopharmacology 4 (3), 138-142, 1984
991984
Single-vs multiple-dose pharmacokinetics of clozapine in psychiatric patients
MG Choc, F Hsuan, G Honigfeld, WT Robinson, L Ereshefsky, ...
Pharmaceutical research 7, 347-351, 1990
961990
Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables
L Ereshefsky, SR Saklad, MD Watanabe, CM Davis, MW Jann
Journal of clinical psychopharmacology 11 (5), 296-301, 1991
931991
Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients
MW Jann, WH Chang, CM Davis, TY Chen, HC Deng, FW Lung, ...
Psychiatry research 30 (1), 45-52, 1989
621989
Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.
L Ereshefsky, MW Jann, SR Saklad, CM Davis
The Journal of clinical psychiatry 47, 6-15, 1986
461986
Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis
AK Kitten, SA Hallowell, SR Saklad, KE Evoy
Innovations in Clinical Neuroscience 15 (1-2), 16, 2018
392018
Comparison of quetiapine abuse and misuse reports to the FDA Adverse Event Reporting System with other second-generation antipsychotics
KE Evoy, C Teng, VG Encarnacion, B Frescas, J Hakim, S Saklad, CR Frei
Substance Abuse: Research and Treatment 13, 1178221819844205, 2019
342019
Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen.
L Ereshefsky, SR Saklad, T Tran-Johnson, G Toney, RC Lyman, ...
Psychopharmacology bulletin 26 (1), 108-114, 1990
321990
Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
MW Jann, WH Chang, YW Lam, HG Hwu, HN Lin, H Chen, TY Chen, ...
Progress in neuro-psychopharmacology & biological psychiatry 16 (2), 193-202, 1992
311992
Clinical pharmacists' impact on prescribing in an acute adult psychiatric facility
SR Saklad, L Ereshefsky, MW Jann, ML Crismon
Drug intelligence & clinical pharmacy 18 (7-8), 632-634, 1984
291984
系统目前无法执行此操作,请稍后再试。
文章 1–20